source
- Mirum's hepatitis D antibody brelovitug meets primary endpoint in phase 3 trialMirum Pharmaceuticals announced that its experimental antiviral monoclonal antibody brelovitug achieved the primary efficacy goal in a phase 3 study for hepatitis D. The trial results continue a s…
- Coherus trims workforce by 30% as Gyre Therapeutics also cuts staff after acquisitionCoherus Oncology announced a 30% reduction in its workforce as part of a reorganization that narrows its pipeline. The cuts follow a decision to deprioritize a combination therapy across multiple…